Psoriatic Arthritis
Feature
Biosimilars poised to save $54 billion over the next decade
But uncertainty points to savings ranging from $24 billion to $150 billion.
News
Golimumab earns new FDA approvals
The intravenous formulation is now approved for psoriatic arthritis and ankylosing spondylitis, in addition to rheumatoid arthritis.
Conference Coverage
Psoriasis: Biologics bring potential for long-term remission off treatment
GENEVA – The results of an extension study of two pivotal secukinumab studies point to a previously unthinkable concept for severe psoriasis.
From the Journals
High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar
A “nocebo” response to switching from an originator biologic to its biosimilar may be hampering persistence to biosimilar therapy, new research...
Conference Coverage
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
GENEVA – Unique study captures entire Danish population up to age 18.
Latest News
Biologic approved for moderate to severe psoriasis in adolescents
Approval was based on phase 3 data, according to the manufacturer.
Conference Coverage
Genital psoriasis is the worst: Patients sound off
GENEVA – Qualitative study elicits patient perspectives.
Conference Coverage
Ixekizumab has profound impact on genital psoriasis
GENEVA – A swift improvement in the “incredibly debilitating” disease was observed in the randomized trial.
From the Journals
TNF inhibitors associated with fewer side effects than methotrexate in children with psoriasis
An international study provides some needed data on the use of systemic treatments and their toxicities in children with moderate to severe...
Latest News
Launch of adalimumab biosimilar Amjevita postponed
Amgen reached a deal with AbbVie to settle its patent infringement litigation.
From the Journals
Swedish study finds low risk of developing psoriasis in bariatric surgery patients
Obesity puts patients at risk for psoriasis, but bariatric surgery can help change that.